Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822906 | 0.93 | ALDH1A1 (0.53) | ALDH1A1LMNAF2RL3GRM2SMN1; SMN2 | |
| SCHEMBL1909166 | 0.90 | GRM2 (0.53) | ALDH1A1LMNAKLKB1GRM2MAPK1 | |
| SCHEMBL553854 | 0.89 | HSD17B10 (0.60) | ALDH1A1LMNAF2RL3KLKB1GRM2 | |
| SCHEMBL2821953 | 0.89 | LMNA (0.54) | ALDH1A1LMNAKLKB1GRM2SMN1; SMN2 | |
| SCHEMBL28595790 | 0.89 | ESR1 (0.55) | ALDH1A1LMNAKLKB1GRM2SMN1; SMN2 | |
| SCHEMBL30739109 | 0.88 | GRM2 (0.49) | ALDH1A1LMNAF2RL3KLKB1GRM2 | |
| SCHEMBL553801 | 0.88 | GRM2 (0.53) | ALDH1A1LMNAF2RL3KLKB1GRM2 | |
| SCHEMBL3092869 | 0.88 | HSD17B10 (0.51) | ALDH1A1LMNAKLKB1GRM2SMN1; SMN2 | |
| SCHEMBL554548 | 0.88 | GRM2 (0.51) | ALDH1A1LMNAKLKB1GRM2SMN1; SMN2 | |
| SCHEMBL16246754 | 0.88 | KLKB1 (0.57) | ALDH1A1LMNAKLKB1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12240818-B2 | Crystalline forms of plasma kallikrein inhibitors | REZOLUTE, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-114867477-B | Crystalline forms of a plasma kallikrein inhibitor | 雷佐鲁特公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240174649-A1 | CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-05-30 | — | — | US | disclosed |
| CN-114502531-B | Process for preparing plasma kallikrein inhibitors | 雷佐鲁特公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-5962439-A | CARDIOVASCULAR DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5849919-A | Fused benzeneoxyacetic acid derivatives which have PGI2 receptor anonist activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0548949-B1 | Fused benzeneoxyacetic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1997-09-17 | — | — | EP | disclosed |
| US-5589496-A | Fused benzeneoxyacetic acid derivatives which have PGI2 receptor agonist activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| US-5389666-A | Administering for treatment and prevention of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer or hypertension | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0548949-A2 | Fused benzeneoxyacetic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | ALDH1A1 2654/4885LMNA 3558/4885F2RL3 149/4885 |
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | ALDH1A1 1178/4885LMNA 4664/4885F2RL3 25/4885 |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | ALDH1A1 3106/4885LMNA 4691/4885F2RL3 4199/4885 |
| US-20240309003-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ALDH1A1 2654/4885LMNA 3558/4885F2RL3 149/4885 |
| US-20240174649-A1 | CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE | CUL4A, CUL1, CUL3 | ALDH1A1 1864/4885LMNA 2544/4885F2RL3 3143/4885 |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | ALDH1A1 2654/4885LMNA 3558/4885F2RL3 149/4885 |
| US-12240818-B2 | Crystalline forms of plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | ALDH1A1 3341/4885LMNA 748/4885F2RL3 40/4885 |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | DAO, DDO, AOX1 | ALDH1A1 622/4885LMNA 4772/4885F2RL3 529/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | ALDH1A1 3106/4885LMNA 4691/4885F2RL3 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.